Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 10 of 10 entries
View as:

PD-1 Inhibition in Advanced Myeloproliferative Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT03065400 Org: User:
Start: 06/14/17 End: 05/28/20 Due: 05/28/21

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

Phase: N/A Priority: Normal
NCT ID: NCT02076191 Org: User:
Start: 02/28/14 End: 07/20/18 Due: 07/20/19

MPN-RC 118 AVID200 in Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT03895112 Org: User:
Start: 02/15/19 End: 05/16/22 Due: 05/16/23

Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00572897 Org: User:
Start: 08/31/07 End: 06/15/15 Due: 06/15/16

Anti-TGF-beta Therapy in Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01291784 Org: User:
Start: 02/28/11 End: 01/31/13 Due: 01/31/14

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01790295 Org: User:
Start: 11/30/13 End: 10/26/17 Due: 10/26/18

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

Phase: N/A Priority: Normal
NCT ID: NCT01693601 Org: User:
Start: 01/31/13 End: 05/18/18 Due: 05/18/19

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Phase: N/A Priority: Normal
NCT ID: NCT02407080 Org: User:
Start: 04/30/15 End: 12/19/18 Due: 12/19/19

Study of Canakinumab in Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT05467800 Org: User:
Start: 08/02/22 End: 07/01/27 Due: 07/01/28

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04281498 Org: User:
Start: 01/14/21 End: 05/30/23 Due: 05/30/24